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Inhibition of glomerular glucosaminyl N-deacetylase in diabetic rats.
The enzyme glucosaminyl N-deacetylase plays a key role in heparan
sulphate biosynthesis since N-deacetylation is a prerequisite for N- and
further 0-suiphation of the carbohydrate polymer. Diabetes induced
inhibition of this enzyme could be an important factor in the develop-
ment of diabetic nephropathy. In this study glomerular glucosaminyl
N-deacetylase activity and urinary albumin excretion were measured in
insulin-treated streptozotocin-diabetic rats. Furthermore, in an attempt
to provide evidence of genetically dependent differences in the vulner-
ability of the N-deacetylase enzyme, two closely related rat strains (H
and U) were studied. A significant 10% inhibition in enzyme activity
was found among rats with mean blood glucose values between 9 and 17
mmol/liter, P < 0.05. There was a pronounced difference between the
two rat strains in the vulnerability of the enzyme against blood glucose
alterations. The U rat appeared highly sensitive to short-term blood
glucose control judged by the correlation between blood glucose and
N-deacetylase activity (r = —0.73, P = 0.005, N = 16), where no such
correlation was found in the H rat (r = 0.02, P = 0.9, N = 14). Urinary
albumin excretion was increased in diabetic H rats and significantly
correlated to glomerular N-deacetylase activity (r = —0.62, P = 0.02, N
= 14). The U rats developed a 10-fold rise in albumin excretion
compared to H rats, but this albuminuria was apparently not related to
the presence of diabetes or correlated to glomerular N-deacetylase
activity. It is concluded that the diabetes induced inhibition of glucos-
aminyl N-deacetylase may play an important role in the pathogenesis of
diabetic nephropathy.
Experimental diabetes impairs heparan sulphate synthesis
[1—31 and decreases the degree of heparan sulphate suiphation
[4—7]. Both reduced concentration and reduced suiphation of
heparan sulphate may lead to increased glomerular permeability
due to loss of glomerular basement membrane fixed negative
charge [8]. Thus, diabetes-induced alterations of cellular and
basement membrane heparan sulphate may represent an impor-
tant pathogenic mechanism in the development of diabetic
nephropathy.
The enzyme glucosaminyl N-deacetylase (N-Acetylheparo-
san-deacetylase) plays a key role in the biosynthesis of heparan
sulphate, since N-deacetylation of heparan sulphate glu-
cosamine units is a prerequisite to N-sulphation and further
modifications of the polymer [9, 10]. Inhibition of the
N-deacetylase activity will therefore impair the suiphation of
heparan sulphate. We have recently demonstrated that experi-
mental diabetes induces a marked inhibition of hepatic
N-deacetylase activity [11]. The aim of the present study was to
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see if the inhibition of N-deacetylase could also be demon-
strated in glomeruli from diabetic rats, and if glomerular
N-deacetylase activity was correlated to the development of
albuminuria.
Furthermore, intraindividual differences in the risk of devel-
oping diabetic nephropathy may be related to differences in the
vulnerability of N-deacetylase enzyme [12]. We therefore stud-
ied two genetically different Sprague-Dawley rat strains, de-
noted H and U, in an attempt to provide evidence of genetically
dependent differences in the vulnerability of this enzyme. The
U rats are characterized by diabetes induced alterations in the
synthesis of extracellular matrix components and rate of skel-
etal malformations among the offspring [13—15], and a previous
study has suggested that N-deacetylase in the U rats might be
highly prone to diabetes induced inhibition [11].
Methods
Study design
Male H and U Sprague-Dawley rats (weight 90 to 110 g) were
used. H rats were standard Sprague-Dawley rats (from Zentra-
linstitut für Verzuchstiere, Hannover, Germany), U rats origi-
nated from the Hannover strain, but have been bred separately
since 1962 in Uppsala, Sweden, and are currently found at the
University of Uppsala, Department of Medical Cell Biology
[13]. Diabetes was induced by i.v. injection of streptozotocin
(Sigma S-0130) 55 mg/kg in 0.05 mol/liter citrate buffer pH 4.2.
Exclusion due to insufficient diabetes induction was decided if
blood glucose measured four days after the injection was below
20 mmol/liter. All animals were insulin treated (one daily
injection s.c. of Ultra Lente Bovine heat-treated insulin, Novo),
and randomized to blood glucose control in the range 6 to 10
mmol/liter or 10 to 15 mmol/liter, to create a differential range in
metabolic control. Free access was allowed to water and
standard fodder. Morning blood glucose was measured daily.
Twenty-four hour urines were sampled with four-week intervals
in order to measure urinary albumin excretion rate. After 12
weeks the animals were killed by decapitation. Non-diabetic
rats from each strain were included as controls.
Sample preparation
Both kidneys were rapidly removed, allowed to bleed out and
weighed after removal of the perirenal capsule. Glomeruli were
isolated using sequential sieving through 200, 150 and 75 s mesh
sieves with 0,01 mol/liter phosphate buffeted 0.15 mol/liter
saline pH 7.4 at 5°C [16]. All preparations were checked for
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purity by microscopy, and the number of glomeruli was counted
in five 10 .d aliquots out of a total volume of 10 ml. After
centrifugation (300 rpm, 1 mm), glomeruli were finally resus-
pended in 300 j.d hypotonic detergent buffer (0.05 molt! Tris 1%
Triton-X-!00), left at room temperature for 10 minutes and
subsequently centrifuged for five minutes at 12,000 g.
N-deacetylase activity and protein concentration were mea-
sured on the supernatant, that is the microsomal cell fraction.
The efficiency of the extraction procedure was tested in a
control experiment where glomeruli were homogenized by
ultrasonication. Whereas the latter procedure increased the
amount of protein extracted, no extra N-deacetylase activity
was found.
N-deacetylase assay
The assay followed essentially the method by Navia et al [17],
using N-[3H]acetyl labeled E. co/i KS capsular po!ysaccharide
as substrate. The polysaccharide was kindly donated by Dr. G.
van Deedem (from Diosynth By, The Netherlands). This ma-
terial was further purified on an ionexchange column (DEAE)
with a salt gradient elution (0.05 to 1.5 M NaC1) at pH 4. [3F1J
labeled acetyl was incorporated as N-acetyl groups as described
earlier [171. The size of the labeled substrate was 50,000 to
60,000 kD, measured by chromatography on Superose gel hplc
column (Pharmacia Uppsala, Sweden). Glomerular microsomal
fraction (0.15 to 0.3 mg protein) was incubated with substrate,
5 mgtliter, in 50 mmoltliter MES 10 mmoltliter MnCI2 pH 6.3, in
a total volume 200 d. After 30 minutes at 37°C the reaction was
terminated by addition of 200 pi stopping solution (I M mono-
chloracetic acid, 0.5 M NaOH, 2 M NaCI). The released
[3H]acetate was measured by scintillation counting in a biphasic
system with 5 ml scintillation fluid [Optiscint "Safe" Pharmacia
LKB with 10% isoamyl alcohol (MERCK 979)] added to the
assay mixture. Blind samples, where the stopping solution was
added prior to the substrate, were included for each sample.
Samples were measured in duplicate. Between and within assay
coefficients of variation were 10% and 3%, respectively.
Urinary albumin
Urinary albumin was measured with a four-layer sandwich
enzyme-linked immunoassay. Briefly, maxisorb microtiter
plates (NUNC, Roskilde, Denmark) were coated with rabbit
anti-rat albumin (RARaJalb, from NORDIC, Tilburg, The Neth-
erlands) diluted 1:16.000 in 0.1 moltliter sodium carbonate
buffer, pH 9.8. The plates were washed in 0.1 moltliter NaC1
0.05% Tween, whereafter samples and standard, purified rat
albumin fraction V (ICN) in the range 1.3 to 100 gt1iter diluted
in 0.04 moltliter phosphate buffer 0.1 mol/liter NaCl 0.5%
bovine serum albumin and 0.05% Tween, pH 7.4, were added.
After overnight incubation at 5°C and wash, the wells were
incubated with biotinylated RARaIalb (Biotin-X-NHS, from
Calbiochem) for four hours at room temperature, washed again
and incubated with streptavidin-peroxidase 0.05 mg/liter for
two hours. Finally, peroxidase activity coupled to solid phase
was visualized at 450 nm with Microwell Peroxidase Substrate
System (TMB, Kierkegaard and Perry, Gaithersburg, Mary-
and, USA). Between and within assay coefficients of variation
were 8% and 4%, respectively.
Table 1. Distribution (mean SD) of glomerular number, extractable
protein, and kidney weight between the four groups
H URat strain
Group Non-diabetic Diabetic Non-diabetic Diabetic
N (7) (14) (8) (16)
Number of 30.6 8 31.3 6 28.7 6 30.1 6
glomeruli (l0)
Protein per io 71 16 73 15 66 13 65 15
glomeruli ,tg
Kidney weight g 2.66 0.2 2.94 0.3 2.89 0.5 3.37 0.4
Glomeruli were purified from the kidneys of insulin treated strepto-
zotocin diabetic Sprague-Dawley rats (H and U strains) and non-
diabetic rats.
Other measurements
Total protein was measured with BCA Protein Assay Reagent
(Pierce) using human reference serum (Orion Diagnostics,
Espoo, Finland) as the standard. Hemoglobin A, was mea-
sured by ion exchange chromatography on a Bio-Rad Diamat
autoanalyzer. Other measurements performed on a Cobas Mira
analyzer were blood glucose, serum creatinine and urine creat-
mine.
Statistics
Two-tailed non-parametric statistics (Mann-Whitney rank
sum test, Spearmann rank correlation, and Kruskall Wallis
one-way analysis by ranks) were used. P-values below 0.05
were considered significant. Results are expressed as median
and range unless otherwise stated.
Results
Metabolic control
In diabetic rats the hemoglobin A1 was in the range 1.0 to
2.2% (compared to 0.8 to 1.0% in non-diabetic rats), and the
mean of all blood glucose measurements of the last two weeks
ranged from 5.9 to 17.6 mmoltliter, without difference between
H and U rats. Urine volume during the 12th week sampling was
21 (8 to 64) mI/24 hr in the diabetic rats and 12 (8 to 50) m1124 hr
in non-diabetic rats. The increase in weight was 383 62 g
(mean SD) among the diabetic animals and 386 66 g among
controls.
Glomerular sampling
More than 90% of the sampled elements were isolated gb-
meruli. The mean number of glomeruli sampled per animal was
30,300, and mean amount of extracted protein was 2.1 mg
(Table 1). The values were slightly higher in H rats compared to
U rats, but did not differ among diabetic and non-diabetic
animals and were not correlated to blood glucose control.
N-deacetylase
Diabetic animals with blood glucose levels above the median
(BG: 8,9 to 17.6 mmol/liter) had significantly reduced
N-deacetylase activity [2.72 (2.11 to 3.52) cpm l0 . mg
protein 'I compared to diabetic rats with blood glucose levels
below the median [3.03 (2.45 to 4.121 and non-diabetic animals
[3.03 (2.33 to 3.22), Kruskall Wallis P 0.046]. There was a
significant correlation between N-deacety!ase activity and
Fig. 1. Correlation between blood glucose control and glomerular glucosaminyl N-deacetylase activity in insulin treated streptozotocin diabetic
Sprague-Dawley rats (0 = H and • = U strains). Effects of both long- and short-term control were studied and the correlations were assessed
by Spearman rank correlation test. A. Pooled data from both strains, long-term control (mean of two weeks daily blood glucose measurements),
the correlation was significant (r = —0.52 P = 0.006). B. H rats only, short-term control (mean of last 24 hours blood glucose measurements), no
significant correlation was found (r = 0.02 P = 0.9). C. U rats only, short-term control, a significant correlation was found (r = —0.73 P = 0.005).
blood glucose control among the diabetic animals (Fig. IA).
Thus negative correlations were found both with mean of the
last two weeks blood glucose values (r =
—0.52, P 0.006),
with hemoglobin A1 (r = —0.48, P = 0.01), and with mean of
last 24 hours blood glucose, that is, the mean of the last two
morning blood glucose concentrations (r —0.38, P = 0.04).
However, when H and U rats were analyzed separately, the
correlation to mean of the last two weeks blood glucose was
less pronounced among the H rats (r =
—0.49, P = 0.08) than
among U rats (r =
—0.68, P = 0.008). Furthermore, correlation
to mean of last 24 hours blood glucose was completely absent
among H rats (r = 0.02, P = 0.9), whereas it was very
significant among the U rats (r =
—0.73, P = 0.005; Fig. lB and
C). No difference in N-deacetylase activity was found between
nondiabetic IT and U rats [H: 3.04 (2.33 to 3.22); U: 2.95 (2.60
to 3.26)].
Kidney function
Diabetic H rats had significantly elevated urinary albumin
excretion at the end of the study period compared to non-
diabetic H rats [1.8 (0.2 to 5.7) vs. 0.5 (0.2 to 0.8) mg/24 hours;
P 0.03; Fig. 21. Urinary albumin excretion was significantly
elevated in the U rats compared to H rats at all measurements
(P < 0.001, Fig. 2). There was no difference in albumin
excretion between diabetic and non-diabetic U rats at the end of
the study period [5.9 (0.7 to 23.6) vs. 8.8 (0.6 to 31.7)].
N-deacetylase activity was correlated to urinary albumin
excretion (r =
—0.62, P = 0.02) in the diabetic H rats (Fig. 3).
Neither metabolic control, amount of protein extracted per
glomerulus nor kidney weight shared this correlation to urinary
albumin excretion. No correlation between these parameters
and urinary albumin excretion as found among the U rats.
Creatinine clearance, measured after 12 weeks, was compa-
rable in diabetic (H; 0.61 0.1 mI/mm per g kidney; U: 0.51
0.1) and non-diabetic rats (H: 0.62 0.1; U: 0.78 0.1).
I— — - I I I
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Fig. 2. Diurnal urinary albumin excretion (mean and SEM) in insulin-
trea ted streptozotocin diabetic Sprague-Dawley rats (H and U strains)
and non-diabetic rats. Four measurements were performed during a 12
week study period. Symbols are: H rats, dashed lines; U rats, solid
lines; (•) diabetic; (0) non-diabetic. After 12 weeks the difference
between diabetic and non-diabetic H rats was significant (P = 0.03,
Mann-Whitney test). No difference was found between diabetic and
non-diabetic U rats. The difference between H and U rats was signifi-
cant at all measurements (P < 0.001).
Discussion
The heparan sulphate polysaccharide chains are initially
composed of D-glucuronic acid (GlcA) and N-acetyl-D-glu-
cosamine (G1cNAc) units in a (GlcA-GlcNAc) structure. The
subsequent modification of the polysaccharide is initiated by
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Fig. 3. Correlation between glomerular glucosaminyl N-deacetylase
activity and diurnal urinary albumin excretion in insulin-treated strep-
tozotocin diabetic, standard Sprague-Dawley rats (H strain). A signif-
icant correlation was found, r =
—0.62, P = 0.02 (Spearman rank
correlation test).
C5-epimerization of glucuronic acid and 0-suiphation in various
positions, both of which appear to occur exclusively in the
vicinity of previously incorporated N-sulphate groups [re-
viewed in 9, 10]. The initial step, that is, N-deacetylation, is
catalyzed by the N-deacetylase, and inhibition of this enzyme
will therefore impair the sulphation of heparan sulphate.
The aim of this study was to see if glomerular N-deacetylase
activity is inhibited by diabetes and if such an inhibition is
correlated to the development of albuminuria. Furthermore, the
study was designed to disclose differences in diabetes induced
inhibition of the N-deacetylase between two closely related rat
strains.
The observation period was chosen to allow for significant
development of albuminuria. It was, on the other hand, consid-
ered important to limit the observation period to avoid major
alterations in glomerular morphology, since alteration in the
ratio between the different glomerular tissue components (such
as, by mesangial expansion, glomerular sclerosis, etc.) could
influence the interpretation of the enzyme activity in the gb-
merular cell extracts. The diabetic animals were randomized to
different levels of blood glucose control, and it is therefore
unlikely that intrinsic factors such as streptozotocin toxicity or
preserved 13-cell function would be responsible for a correlation
between glucose control and N-deacetylase activity. The in-
tended levels of blood glucose control ranged from "optimal"
(BG: 6 to 10 mmol/liter) to "moderately poor" control (BG: 10
to 15 mmol/liter) to avoid irrelevant effects of severe diabetic
metabolical disturbances on the N-deacetylase activity. The
insulin treatment regimen has previously been shown to create
steady glucose levels [18]. Average morning blood glucose level
is therefore a reliable parameter of blood glucose control.
The study demonstrates that glomerular N-deacetylase activ-
ity is inhibited by diabetes and that the degree of inhibition
correlates to blood glucose control. This fits in with our
previous finding of diabetes induced inhibition of hepatic
N-deacetylase activity [11]. In the present study, N-deacetylase
activity was measured at a non-saturating substrate concentra-
tion (15% of the Michaelis constant, Km), because the assay
does not allow V measurements at very low enzyme con-
centrations. We have previously shown that diabetes induces a
reduction in N-deacetylase Km [111. This would increase the
N-deacetylase activity at low substrate concentrations. The
reduction in N-deacetylase activity found in this study is
therefore likely to reflect an even larger reduction in 'Sjmax
activity. Recently it has been demonstrated that N-deacetylase
activity depends on the concerted action of two protein com-
ponents [19]. The cause of the diabetes induced decrease in
activity seems to be a specific reduction in the amount of the
110 kDa glycoprotein component (E. Unger, personal commu-
nication).
Furthermore, it was found that the correlation between blood
glucose and N-deacetylase activity was more pronounced in U
rats than in H rats, indicating higher vulnerability of N-deacety-
lase against blood glucose alterations in U rats. This difference
between the two rat strains remains unexplained. However, we
believe it to be a valid observation since the same difference
was observed previously in studies of hepatic N-deacetylase
[11, and unpublished data from that study].
Diabetic H rats had increased urinary albumin excretion.
Interestingly, the rate of albumin excretion was correlated to
glomerular N-deacetylase activity rather than to any other
parameters measured, including blood glucose control. This
might suggest a causative relation between impaired N-deacety-
lase activity and the development of albuminuria in the diabetic
H rats.
The U rats developed a very significant albuminuria, the
cause of which remains unknown since it was apparently not
related to glomerular N-deacetylase activity or to blood glucose
control. The routine microscopy of the glomerular preparations
unveiled no differences between H and U rats. We have
followed several generations of this rat strain and found that the
albuminuria is an inherited quality, expressed in both male and
female U rats. Thus it is possible that in the U rats the expected
correlation between N-deacetylase activity and urinary albumin
excretion is drowned by the effect of an overlapping renal
abnormality.
The results indicate that diabetes induces a widespread
inhibition of the glucosaminyl N-deacetylase. The consequence
of this inhibition is expected to be synthesis of undersulphated
heparan sulphate molecules, which will be incapable of normal
interaction with other basement membrane components. Within
the glomerulus this may cause mesangial growth and increased
glomerular permeability leading to progression of glomerulo-
sclerosis [8, 20]. Also, the antithrombogenic properties of
heparan sulphate in the plasma membrane of endothelial cells
depend on the degree sulphation [21—23], and reduced sub-
phation could therefore lead to acceleration of atherogenesis as
commonly found in patients developing diabetic nephropathy
[24].
It is still unknown why some diabetic patients are more
susceptible to the development of severe late diabetic compli-
cations, but we have hypothesized that these patients might be
characterized by having a relatively increased amount of
N-deacetylase iso-enzymes which are extremely vulnerable to
poor diabetes control 1121. The demonstration of significant
differences in the vulnerability of the N-deacetylase between
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N-deacetylase iso-enzymes. Obviously, any of the still un-
known factors involved in the regulation of the N-deacetylase
activity might cause the apparent differences in N-deacetylase
vulnerability.
In conclusion, glomerular N-deacetylase activity is inhibited
by diabetes. The degree of inhibition correlates to the degree of
albuminuria in standard Sprague-Dawley rats (H). The U rats
appear highly susceptible to diabetes-induced inhibition of
N-deacetylase activity, but present in addition a predisposition
to development of albuminuria not directly related to the
activity of the N-deacetylase. The inhibition of the N-deacety-
lase may have clinical significance, and so may the unknown
mechanism behind differences in N-deacetylase vulnerability.
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